Dana Summons

Dana A. Summons serves as a key procurement professional within the National Cancer Institute, supporting the agency’s mission to accelerate cancer research through strategic acquisition of scientific and technical services. Responsible for managing complex contracts aligned with biomedical innovation, Summons oversees the procurement of research and development services critical to advancing precision medicine, diagnostic technologies, and therapeutic discovery. Their work directly enables the Institute’s scientific priorities by securing specialized expertise in life sciences research, biotechnology, and professional scientific consulting, ensuring alignment with federal acquisition regulations and NIH strategic goals. Summons maintains a consistent working relationship with Quality Biological, Inc., a primary contractor providing specialized biological reagents and research support services essential to NCI’s laboratory and translational research programs. This partnership reflects a pattern of sustained engagement with vendors offering high-integrity, mission-critical scientific materials and technical support, often under long-term or task-order arrangements. The procurement approach emphasizes reliability, regulatory compliance, and scientific validity, prioritizing vendors with proven expertise in GMP-grade biological products and research-grade instrumentation. Set-aside preferences indicate a strong emphasis on open competition, with 83.3% of awards issued without socioeconomic set-asides, reflecting a preference for full and open procurement where technical merit drives selection. However, a meaningful 16.7% of contracts are structured as total small business set-asides under FAR 19.5, demonstrating a deliberate commitment to fostering innovation from small business entities without compromising scientific rigor. The procurement portfolio is heavily concentrated in NAICS 541715 (R&D in life sciences) and 541990 (other professional scientific services), with additional focus on biotechnology research (541714) and scientific consulting (541690). Summons routinely acquires services related to preclinical research, assay development, bioinformatics, and laboratory support, reflecting deep technical familiarity with the biomedical R&D lifecycle and the specialized vendor ecosystem supporting cancer research.